We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note
Read MoreHide Full Article
DaVita HealthCare (DVA - Free Report) ended the recent trading session at $174.67, demonstrating a -4.62% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily loss of 0.03%. Meanwhile, the Dow experienced a drop of 0.31%, and the technology-dominated Nasdaq saw an increase of 0.01%.
The stock of kidney dialysis provider has risen by 1.72% in the past month, leading the Medical sector's loss of 4.15% and the S&P 500's gain of 0.53%.
Analysts and investors alike will be keeping a close eye on the performance of DaVita HealthCare in its upcoming earnings disclosure. On that day, DaVita HealthCare is projected to report earnings of $3.78 per share, which would represent year-over-year growth of 50.6%. Meanwhile, our latest consensus estimate is calling for revenue of $3.53 billion, up 3.23% from the prior-year quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $14.57 per share and a revenue of $14.28 billion, representing changes of +35.16% and +4.67%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for DaVita HealthCare. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. DaVita HealthCare presently features a Zacks Rank of #3 (Hold).
In the context of valuation, DaVita HealthCare is at present trading with a Forward P/E ratio of 12.57. This indicates a discount in contrast to its industry's Forward P/E of 20.04.
It is also worth noting that DVA currently has a PEG ratio of 0.47. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Outpatient and Home Healthcare industry currently had an average PEG ratio of 1.73 as of yesterday's close.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This group has a Zacks Industry Rank of 31, putting it in the top 13% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note
DaVita HealthCare (DVA - Free Report) ended the recent trading session at $174.67, demonstrating a -4.62% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily loss of 0.03%. Meanwhile, the Dow experienced a drop of 0.31%, and the technology-dominated Nasdaq saw an increase of 0.01%.
The stock of kidney dialysis provider has risen by 1.72% in the past month, leading the Medical sector's loss of 4.15% and the S&P 500's gain of 0.53%.
Analysts and investors alike will be keeping a close eye on the performance of DaVita HealthCare in its upcoming earnings disclosure. On that day, DaVita HealthCare is projected to report earnings of $3.78 per share, which would represent year-over-year growth of 50.6%. Meanwhile, our latest consensus estimate is calling for revenue of $3.53 billion, up 3.23% from the prior-year quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $14.57 per share and a revenue of $14.28 billion, representing changes of +35.16% and +4.67%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for DaVita HealthCare. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. DaVita HealthCare presently features a Zacks Rank of #3 (Hold).
In the context of valuation, DaVita HealthCare is at present trading with a Forward P/E ratio of 12.57. This indicates a discount in contrast to its industry's Forward P/E of 20.04.
It is also worth noting that DVA currently has a PEG ratio of 0.47. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Outpatient and Home Healthcare industry currently had an average PEG ratio of 1.73 as of yesterday's close.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This group has a Zacks Industry Rank of 31, putting it in the top 13% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.